DOCSLIB.ORG

Clinical Significance of Prognostic and Predictive Markers in Colorectal

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Clinical Significance of Prognostic and Predictive Markers in Colorectal The Pharmacogenomics Journal (2002) 2, 209–216 2002 Nature Publishing Group All rights reserved 1470-269X/02 $25.00 www.nature.com/tpj CLINICAL IMPLICATION multiple genetic abnormalities are Clinical significance of prognostic accumulated over time during the pro- gression from adenoma to adenocarci- and predictive markers in colorectal noma (Figure 1).1 Mutations in genes such as the Kirsten-ras (K-ras), aden- cancer omatous polyposis coli (APC), deleted in colon cancer (DCC) and the p53 DB Longley, U McDermott and PG Johnston tumour suppressor gene are the most common genetic alterations found in Department of Oncology, Cancer Research Centre, Queen’s University Belfast, Belfast, sporadic CRC. Approximately 5% of Northern Ireland CRC is inherited and familial aden- omatous polyposis (FAP) and heredi- tary non-polyposis colon cancer The Pharmacogenomics Journal (2002) 2, fication and microsatellite instability (HNPCC) are the most well-charac- 209–216. doi:10.1038/sj.tpj.6500124 (MSI). In addition, the expression of terized syndromes.2 FAP is caused by individual genes can be assessed at the mutations in the APC gene, whereas INTRODUCTION levels of mRNA and protein using the 90% of HNPCC cases are caused by Colorectal cancer (CRC) is the second techniques of real-time reverse tran- mutations in genes involved in mis- most common cause of cancer death scription PCR and immunohistochem- match repair (MMR) leading to in the US. Approximately 130 000 new istry (IHC) respectively. The ultimate microsatellite instability (MSI). In cases of CRC are diagnosed in the US goal of this research is the tailoring of addition, 10–15% of sporadic cases of each year with an annual mortality of treatment to the molecular pheno- CRC have mutations in MMR genes. approximately 56 000 people. In the types of tumour and patient. This post-operative setting, there is clear review highlights potentially Loss of heterozygozity (LOH) evidence that offering adjuvant ther- important prognostic and predictive More than 75% of CRCs have lost a apy significantly improves survival in markers in CRC. Due to space restric- portion of chromosome 17p or 18q, or stage III CRC, however, the manage- tions many worthy contributions both. The 17p segment contains p53, ment of stage II disease is an area of could not be cited. which is regarded as one of the most controversy and debate. The 5-year important tumour suppressor genes. It survival for stage II patients is approxi- Colorectal Cancer Biology has a number of key functions such as mately 75%, indicating that the The genetic model of CRC proposed DNA damage repair, initiation of cell majority are cured by surgery alone, by Vogelstein and others suggests that cycle checkpoints and initiation of and many patients who would have been cured by surgery undergo chemo- therapy unnecessarily. Furthermore, Table 1 Prognostic molecular markers in colorectal cancer some patients who are not rec- ommended to receive adjuvant treat- Marker Measurement technique Comments ment may benefit from chemotherapy. Recent studies have started to define p53(LOH 17p) IHC, DNA sequencing p53 overexpression measured by IHC generally prognostic molecular markers that associated with worse prognosis, however, not a identify those patients at risk of consistent observation. p53 mutation by sequencing associated with shorter survival time. relapse after surgery and who may LOH 18q RFLP, PCR, Southern Blot Associated with worse prognosis. Locus contains benefit most from chemotherapy 3 potential tumour suppressor genes: DCC, (Table 1). Furthermore, molecular mar- Smad2, Smad4. kers are being identified that predict LOH 8p RFLP, PCR, Southern Blot Associated with worse prognosis. Identity and whether a tumour will respond to a function of genes at this locus not determined. particular chemotherapy. In addition, MSI PCR MSI-H tumours associated with survival some markers may have therapeutic advantage and less aggressive clinical course. value by predicting the degree of sys- K-ras SSCP, DNA sequencing Some studies have found an association between K-ras mutation and survival, but others have not. temic toxicity for a particular treat- The particular type of mutation may be ment. For such studies tumour DNA important. can be analysed to identify genetic TS IHC, RT-PCR, genotyping High TS expression and TSER*3/TSER*3 genotype changes such as point mutations, loss associated with worse clinical outcome. of heterozygosity (LOH), gene ampli- Molecular markers for colorectal cancer DB Longley et al 210 Chromosome: 5q 12p 18q 17p Alteration: loss/mutation Mutation loss loss/mutation Gene: APC K-ras DCC, Smad 2/4 p53 Other alterations DNA methylation changes Normal Hyperprolif Early Intermediate Late Carcinoma Metastasis epithelium epithelium Adenoma Adenoma Adenoma Figure 1 A genetic model for colorectal carcinogenesis (adapted from Fearon and Vogelstein1). apoptosis.3 p53 has been the most whereas those without p53 over- cer and appear to have tumour sup- extensively studied molecular marker expression did.13 However, other stud- pressor functions.20 in patients with CRC and mutations ies have found no correlation between Loss of material from the short arm have been found in 40–60% of cases.2 p53 status and response to 5FU-based of chromosome 8 is found in approxi- Missense mutations of the p53 gene chemotherapy.14 mately 50% of cases of CRC. The intro- result in production of a protein with Allelic loss on chromosome 18q is duction of chromosome 8p into colon a longer half-life, therefore, detection found in approximately 70% of CRCs cancer cell lines has been shown to of increased p53 expression by IHC and has been associated with worse decrease their tumourigenecity and has been used as a surrogate for p53 prognosis in stage II and III invasiveness.21 Furthermore, LOH at mutation in many studies. However, tumours.15,16 Jen et al found that stage 8p has been shown to correlate with this assumption has been shown to be II patients who retained both 18q the presence of micrometastases.22 valid in only 60–80% of cases in stud- alleles have an excellent 5-year sur- Halling et al found that in stage II and ies that have compared p53 expression vival of 93% compared to 54% of III CRCs 8p allelic imbalance was an measured by IHC with p53 mutations those who had lost one allele.16 This independent prognostic indicator for analysed by DNA sequencing.4 Despite data suggests that patients with stage decreased survival and time to recur- numerous investigations into the II disease who have a deletion on chro- rence.23 This was the first large study prognostic value of p53 over- mosome 18q have a more aggressive exploring the role of 8p allelic imbal- expression in patients with CRC, the clinical course and may represent a ance in prognosis of CRC. issue still remains controversial. Many subset of stage II patients who would studies have been statistically benefit from adjuvant chemotherapy. Microsatellite instability (MSI) underpowered, and the issue is further Furthermore, a recent study by Watan- MSI is caused by mutations in MMR complicated by the use of different abe et al found that retention of both genes such as hMSH2, hMLH1 and antibodies which have varying levels 18q alleles predicted for favourable hMSH6 resulting in failure of the DNA of sensitivity and capacity for outcome after adjuvant 5FU-based mismatch repair system to correct detecting mutant forms of p53. Studies chemotherapy in stage III CRC.17 The errors that occur during replication. of at least 100 patients with CRC using 18q segment contains three candidate Numerous studies have shown a sur- p53 monoclonal antibodies have gen- tumour suppressor genes: DCC, Smad vival advantage and a less aggressive erally found that p53 overexpression 2 and Smad 4. The product of the DCC clinical course for patients with high was associated with worse prognosis.5,6 gene is a cell adhesion molecule.18 and frequency MSI.23,24 Furthermore, MSI- This association has not been a con- it has been postulated that decreased high tumours have been reported to sistent observation as some studies DCC expression may lead to altered metastasise less often than microsatel- have found the opposite,7 or no corre- adhesion and contribute to enhanced lite stable tumours.24 The MSI pheno- lation.8,9 However, the majority of tumour growth and metastatic spread type also appears to be associated with DNA sequencing studies have shown a of colorectal tumours. Smad proteins excellent survival in patients who significantly shorter survival time in are transcription factors involved in receive adjuvant 5FU-based chemo- patients with mutant p53.10 Data from the transforming growth factor ␤ therapy.25 A recent study found that studies in cell line models have sug- (TGF-␤) pathway.19 These proteins are 61% of stage III CRC patients with gested that p53 status influences 5FU involved in signalling from TGF-␤ MSI-high tumours had a mutation in chemosensitivity.11,12 This has been receptors and regulate transcription of the gene for the type II receptor for borne out in several clinical studies, target genes including c-myc, CBFA1, TGF␤-1.17 Furthermore, these patients for example Ahnen et al found that FLRF and furin. Targeted disruption of had a 74% 5-year survival following patients with stage III CRC whose Smad genes in mice has revealed their adjuvant 5FU-based chemotherapy tumours overexpressed p53 did not importance in embryonic develop- compared to 46% in patients with derive significant survival benefit from ment. Furthermore, Smad 2 and Smad MSI-high tumours that lacked the adjuvant 5FU-based treatment, 4 have been implicated in human can- mutation. Thus, mutation of the gene The Pharmacogenomics Journal Molecular markers for colorectal cancer DB Longley et al 211 for the type II receptor for TGF␤-1 may activated by addition of a farnesyl used in the treatment of metastatic predict the response of MSI-high group, therefore, inhibitors of farnesyl CRC, and recent studies have begun to tumours to 5FU-based chemotherapy.
Load more

Recommended publications
  • Activation of Smad Transcriptional Activity by Protein Inhibitor of Activated STAT3 (PIAS3)
    Activation of Smad transcriptional activity by protein inhibitor of activated STAT3 (PIAS3) Jianyin Long*†‡, Guannan Wang*†‡, Isao Matsuura*†‡, Dongming He*†‡, and Fang Liu*†‡§ *Center for Advanced Biotechnology and Medicine, †Susan Lehman Cullman Laboratory for Cancer Research, Department of Chemical Biology, Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, and ‡Cancer Institute of New Jersey, 679 Hoes Lane, Piscataway, NJ 08854 Communicated by Allan H. Conney, Rutgers, The State University of New Jersey, Piscataway, NJ, November 17, 2003 (received for review August 22, 2003) Smad proteins play pivotal roles in mediating the transforming of many transcription factors through distinct mechanisms. growth factor ␤ (TGF-␤) transcriptional responses. We show in this PIAS1 and PIAS3 bind and inhibit STAT1 and STAT3 DNA- report that PIAS3, a member of the protein inhibitor of activated binding activities, respectively (19, 20). PIASx␣ and PIASx␤ STAT (PIAS) family, activates TGF-␤͞Smad transcriptional re- were identified through interactions with the androgen receptor sponses. PIAS3 interacts with Smad proteins, most strongly with and the homeodomain protein Msx2, respectively (21, 22). Smad3. PIAS3 and Smad3 interact with each other at the endog- PIASx␣ and PIASx␤ inhibit IL12-mediated and STAT4- enous protein level in mammalian cells and also in vitro, and the dependent gene activation (23). PIAS1, PIAS3, PIASx␣, and association occurs through the C-terminal domain of Smad3. We PIASx␤ also regulate transcriptional activation by various ste- further show that PIAS3 can interact with the general coactivators roid receptors (21, 24–26). PIASy has been shown to antagonize p300͞CBP, the first evidence that a PIAS protein can associate with the activities of STAT1 (27), androgen receptor (28), p53 (29), p300͞CBP.
    [Show full text]
  • Tgfβ-Regulated Gene Expression by Smads and Sp1/KLF-Like Transcription Factors in Cancer VOLKER ELLENRIEDER
    ANTICANCER RESEARCH 28 : 1531-1540 (2008) Review TGFβ-regulated Gene Expression by Smads and Sp1/KLF-like Transcription Factors in Cancer VOLKER ELLENRIEDER Signal Transduction Laboratory, Internal Medicine, Department of Gastroenterology and Endocrinology, University of Marburg, Marburg, Germany Abstract. Transforming growth factor beta (TGF β) controls complex induces the canonical Smad signaling molecules which vital cellular functions through its ability to regulate gene then translocate into the nucleus to regulate transcription (2). The expression. TGFβ binding to its transmembrane receptor cellular response to TGF β can be extremely variable depending kinases initiates distinct intracellular signalling cascades on the cell type and the activation status of a cell at a given time. including the Smad signalling and transcription factors and also For instance, TGF β induces growth arrest and apoptosis in Smad-independent pathways. In normal epithelial cells, TGF β healthy epithelial cells, whereas it can also promote tumor stimulation induces a cytostatic program which includes the progression through stimulation of cell proliferation and the transcriptional repression of the c-Myc oncogene and the later induction of an epithelial-to-mesenchymal transition of tumor induction of the cell cycle inhibitors p15 INK4b and p21 Cip1 . cells (1, 3). In the last decade it has become clear that both the During carcinogenesis, however, many tumor cells lose their tumor suppressing and the tumor promoting functions of TGF β ability to respond to TGF β with growth inhibition, and instead, are primarily regulated on the level of gene expression through activate genes involved in cell proliferation, invasion and Smad-dependent and -independent mechanisms (1, 2, 4).
    [Show full text]
  • 5956.Full.Pdf
    Cancer Therapy: Preclinical Radiation and Transforming Growth Factor-B Cooperate inTranscriptional Activation of the Profibrotic Plasminogen Activator Inhibitor-1 Gene Jurre Hageman,1Bart J. Eggen,3 Tom Rozema,1, 2 Kevin Damman,1 Harm H. Kampinga,1and Robert P. Coppes1, 2 Abstract Radiation-induced fibrosis is an important side effect in the treatment of cancer. Profibrotic pro- teins, such as plasminogen activator inhibitor-1 (PAI-1), transforming growth factor-h (TGF-h), and tissue type inhibitor of metalloproteinases-1 (Timp-1), are thought to play major roles in the development of fibrosis via the modulation of extracellular matrix integrity.We did a detailed anal- ysis of transcriptional activation of these profibrotic genes by radiation and TGF-h. Irradiation of HepG2 cells led to a high increase in PAI-1mRNA levels and a mild increase in Timp-1mRNA lev- els. In contrast,TGF-h1and Smad7 were not increased. Radiation and TGF-h showed strong co- operative effects in transcription of the PAI-1 gene. The TGF-b1 gene showed a mild cooperative activation, whereas Timp-1and Smad7 were not cooperatively activated by radiation and TGF-h. Analysis using the proximal 800 bp of the human PAI-1promoter revealed a dose-dependent increase of PAI-1levels between 2 and 32 Gy g-rays that was independent of latent TGF-h acti- vation. Subsequent site-directed mutagenesis of the PAI-1promoter revealed that mutation of a p53-binding element abolished radiation-induced PAI-1 transcription. In line with this, PAI-1 was not activated in p53-null Hep3B cells, indicating that p53 underlies the radiation-induced PAI-1activation and the cooperativity with theTGF-h/Smad pathway.
    [Show full text]
  • Sensing Relative Signal in the Tgf-Β/Smad Pathway PNAS PLUS
    Sensing relative signal in the Tgf-β/Smad pathway PNAS PLUS Christopher L. Fricka,1, Clare Yarkaa, Harry Nunnsa, and Lea Goentoroa,1 aDivision of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA 91125 Edited by Arup K. Chakraborty, Massachusetts Institute of Technology, Cambridge, MA, and approved February 3, 2017 (received for review July 12, 2016) How signaling pathways function reliably despite cellular varia- Smad4. In their heteromeric form, the Smad proteins are retained tion remains a question in many systems. In the transforming more strongly in the nucleus through reduced export rate, as well as, growth factor-β (Tgf-β) pathway, exposure to ligand stimulates as proposed recently (11), accelerated import rate. Thus, ligand nuclear localization of Smad proteins, which then regulate target activation leads to a net accumulation of the Smad complex in gene expression. Examining Smad3 dynamics in live reporter cells, the nucleus, where it regulates target genes. we found evidence for fold-change detection. Although the level The Tgf-β pathway is a particularly interesting system for of nuclear Smad3 varied across cells, the fold change in the level of testing for fold-change detection because it is known that the nuclear Smad3 was a more precise outcome of ligand stimulation. expression levels of its components vary considerably from cell to The precision of the fold-change response was observed through- cell. A recent study using proximity ligation assay in fixed cells out the signaling duration and across Tgf-β doses, and significantly revealed that the levels of Smad3/4 and Smad2/4 complexes vary increased the information transduction capacity of the pathway.
    [Show full text]
  • TGF-Β Signaling
    biomolecules Review TGF-β Signaling Kalliopi Tzavlaki and Aristidis Moustakas * Department of Medical Biochemistry and Microbiology, Science for Life Laboratory, Uppsala University, Box 582, SE-751 23 Uppsala, Sweden; [email protected] * Correspondence: [email protected]; Tel.: +46-18-4714732; Fax: +46-18-4714441 Received: 18 February 2020; Accepted: 20 March 2020; Published: 23 March 2020 Abstract: Transforming growth factor-β (TGF-β) represents an evolutionarily conserved family of secreted polypeptide factors that regulate many aspects of physiological embryogenesis and adult tissue homeostasis. The TGF-β family members are also involved in pathophysiological mechanisms that underlie many diseases. Although the family comprises many factors, which exhibit cell type-specific and developmental stage-dependent biological actions, they all signal via conserved signaling pathways. The signaling mechanisms of the TGF-β family are controlled at the extracellular level, where ligand secretion, deposition to the extracellular matrix and activation prior to signaling play important roles. At the plasma membrane level, TGF-βs associate with receptor kinases that mediate phosphorylation-dependent signaling to downstream mediators, mainly the SMAD proteins, and mediate oligomerization-dependent signaling to ubiquitin ligases and intracellular protein kinases. The interplay between SMADs and other signaling proteins mediate regulatory signals that control expression of target genes, RNA processing at multiple levels, mRNA translation and nuclear or cytoplasmic protein regulation. This article emphasizes signaling mechanisms and the importance of biochemical control in executing biological functions by the prototype member of the family, TGF-β. Keywords: extracellular matrix; phosphorylation; receptor serine/threonine kinase; signal transduction; SMAD; transcription; transforming growth factor-β; ubiquitylation 1.
    [Show full text]
  • IRF3 Prevents Colorectal Tumorigenesis Via Inhibiting the Nuclear Translocation of Β-Catenin
    ARTICLE https://doi.org/10.1038/s41467-020-19627-7 OPEN IRF3 prevents colorectal tumorigenesis via inhibiting the nuclear translocation of β-catenin Miao Tian1,7, Xiumei Wang1,7, Jihong Sun2,7, Wenlong Lin1, Lumin Chen2, Shengduo Liu3, Ximei Wu 4, ✉ ✉ Liyun Shi5, Pinglong Xu 3, Xiujun Cai 6 & Xiaojian Wang 1 Occurrence of Colorectal cancer (CRC) is relevant with gut microbiota. However, role of IRF3, a key signaling mediator in innate immune sensing, has been barely investigated in CRC. 1234567890():,; Here, we unexpectedly found that the IRF3 deficient mice are hyper-susceptible to the development of intestinal tumor in AOM/DSS and Apcmin/+ models. Genetic ablation of IRF3 profoundly promotes the proliferation of intestinal epithelial cells via aberrantly activating Wnt signaling. Mechanically, IRF3 in resting state robustly associates with the active β- catenin in the cytoplasm, thus preventing its nuclear translocation and cell proliferation, which can be relieved upon microbe-induced activation of IRF3. In accordance, the survival of CRC is clinically correlated with the expression level of IRF3. Therefore, our study identifies IRF3 as a negative regulator of the Wnt/β-catenin pathway and a potential prognosis marker for Wnt-related tumorigenesis, and describes an intriguing link between gut microbiota and CRC via the IRF3-β-catenin axis. 1 Institute of Immunology and Bone Marrow Transplantation Center, The First Affiliated Hospital, School of Medicine, Zhejiang University, 310003 Hangzhou, China. 2 Department of Radiology, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, 310016 Hangzhou, China. 3 The MOE Key Laboratory of Biosystems Homeostasis & Protection and Innovation Center for Cell Signaling Network, Life Sciences Institute, Zhejiang University, 310058 Hangzhou, China.
    [Show full text]
  • Nucleocytoplasmic Shuttling of Smad Proteins
    Cell Research (2009) 19:36-46. npg © 2009 IBCB, SIBS, CAS All rights reserved 1001-0602/09 $ 30.00 REVIEW www.nature.com/cr Nucleocytoplasmic shuttling of Smad proteins Caroline S Hill1 1Laboratory of Developmental Signalling, Cancer Research UK London Research Institute, 44 Lincoln’s Inn Fields, London WC2A 3PX, UK Nuclear accumulation of active Smad complexes is crucial for transduction of transforming growth factor β (TGF-β)- superfamily signals from transmembrane receptors into the nucleus. It is now clear that the nucleocytoplasmic distri- butions of Smads, in both the absence and the presence of a TGF-β-superfamily signal, are not static, but instead the Smads are continuously shuttling between the nucleus and the cytoplasm in both conditions. This article presents the evidence for continuous nucleocytoplasmic shuttling of Smads. It then reviews different mechanisms that have been proposed to mediate Smad nuclear import and export, and discusses how the Smad steady-state distributions in the absence and the presence of a TGF-β-superfamily signal are established. Finally, the biological relevance of continu- ous nucleocytoplasmic shuttling for signaling by TGF-β superfamily members is discussed. Keywords: Smad, nuclear import and export, TGF-β-superfamily signaling, karyopherin, nucleocytoplasmic shuttling Cell Research (2009) 19:36-46. doi: 10.1038/cr.2008.325; published online 30 December 2008 Introduction into three functional classes. The first class are the receptor-regulated Smads or R-Smads (Smad1, 2, 3, 5 The transforming growth factor b (TGF-b) superfam- and 8), which are phosphorylated by the type I receptor ily of ligands, which comprises TGF-bs, Activins, bone kinases on an SXS motif at their extreme C-termini.
    [Show full text]
  • Fos-Jun Interactions That Mediate Transcription Regulatory Speci®City
    Oncogene (2001) 20, 2438 ± 2452 ã 2001 Nature Publishing Group All rights reserved 0950 ± 9232/01 $15.00 www.nature.com/onc Close encounters of many kinds: Fos-Jun interactions that mediate transcription regulatory speci®city Yurii Chinenov1 and Tom K Kerppola*,1 1Howard Hughes Medical Institute, University of Michigan Medical School Ann Arbor, Michigan, MI 48109-0650, USA Fos and Jun family proteins regulate the expression of a Wang et al., 1992). However, only a few of the genes myriad of genes in a variety of tissues and cell types. that mediate the essential functions of speci®c Fos and This functional versatility emerges from their interac- Jun family members have been identi®ed (Bakin and tions with related bZIP proteins and with structurally Curran, 1999; Fu et al., 2000) unrelated transcription factors. These interactions at Fos and Jun family proteins function as dimeric composite regulatory elements produce nucleoprotein transcription factors that bind to AP-1 regulatory complexes with high sequence-speci®city and regulatory elements in the promoter and enhancer regions of selectivity. Several general principles including binding numerous mammalian genes (Curran and Franza, cooperativity and conformational adaptability have 1988). Jun proteins form both homodimers and emerged from studies of regulatory complexes containing heterodimers with Fos proteins, whereas Fos proteins Fos-Jun family proteins. The structural properties of do not form homodimers and require heterodimeriza- Fos-Jun family proteins including opposite orientations tion to bind DNA. The DNA-binding and dimerization of heterodimer binding and the ability to bend DNA can domains among dierent family members are highly contribute to the assembly and functions of such conserved and dierent members of the Fos and Jun complexes.
    [Show full text]
  • The Role of Smad Signaling in Hematopoiesis and Translational Hematology
    Leukemia (2011) 25, 1379–1388 & 2011 Macmillan Publishers Limited All rights reserved 0887-6924/11 www.nature.com/leu SPOTLIGHT REVIEW The role of Smad signaling in hematopoiesis and translational hematology U Blank and S Karlsson Division of Molecular Medicine and Gene Therapy, Laboratory Medicine, Lund Stem Cell Center, Lund University Hospital, Lund, Sweden Hematopoietic stem cells (HSCs) reside in the bone marrow ligands are reflected in vitro, often leading to opposing findings (BM) of adult individuals and function to produce and between in vitro and in vivo systems. regenerate the entire blood and immune system over the In this review, we will discuss the role of TGF-b and Smad course of an individual’s lifetime. Historically, HSCs are among the most thoroughly characterized tissue-specific stem cells. signaling in normal hematopoiesis, featuring aspects of transla- Despite this, the regulation of fate options, such as self-renewal tional hematology, particularly the role of Smad signaling in the and differentiation, has remained elusive, partly because of the development of hematologic malignancies and how the Smad expansive plethora of factors and signaling cues that govern circuitry may be exploited for the purpose of stem cell HSC behavior in vivo. In the BM, HSCs are housed in expansion. It should be emphasized that although some of the specialized niches that dovetail the behavior of HSCs with the findings discussed here come from studies of human and need of the organism. The Smad-signaling pathway, which operates downstream of the transforming growth factor-b patients’ cells, the majority of the data derive from studies in (TGF-b) superfamily of ligands, regulates a diverse set of bio- well-defined mouse models.
    [Show full text]
  • Specific Interactions Between Smad Proteins and AP-1
    Oncogene (2013) 32, 3606–3615 & 2013 Macmillan Publishers Limited All rights reserved 0950-9232/13 www.nature.com/onc ORIGINAL ARTICLE Specific interactions between Smad proteins and AP-1 components determine TGFb-induced breast cancer cell invasion A Sundqvist1, A Zieba2,5, E Vasilaki1,5, C Herrera Hidalgo1,OSo¨ derberg2, D Koinuma3, K Miyazono1,3, C-H Heldin1, U Landegren2, P ten Dijke1,4 and H van Dam1,4 Deregulation of the transforming growth factor b (TGFb) signal transduction cascade is functionally linked to cancer. In early phases, TGFb acts as a tumor suppressor by inhibiting tumor cell proliferation, whereas in late phases, it can act as a tumor promoter by stimulating tumor cell invasion and metastasis. Smad transcriptional effectors mediate TGFb responses, but relatively little is known about the Smad-containing complexes that are important for epithelial–mesenchymal transition and invasion. In this study, we have tested the hypothesis that specific members of the AP-1 transcription factor family determine TGFb signaling specificity in breast cancer cell invasion. Using a 3D model of collagen-embedded spheroids of MCF10A-MII premalignant human breast cancer cells, we identified the AP-1 transcription factor components c-Jun, JunB, c-Fos and Fra1 as essential factors for TGFb- induced invasion and found that various mesenchymal and invasion-associated TGFb-induced genes are co-regulated by these proteins. In situ proximity ligation assays showed that TGFb signaling not only induces complexes between Smad3 and Smad4 in the nucleus but also complexes between Smad2/3 and Fra1, whereas complexes between Smad3, c-Jun and JunB could already be detected before TGFb stimulation.
    [Show full text]
  • Coordinate Transcriptional and Translational Repression of P53 by TGF-B1 Impairs the Stress Response
    Molecular Cell Article Coordinate Transcriptional and Translational Repression of p53 by TGF-b1 Impairs the Stress Response Fernando J. Lo´ pez-Dı´az,1 Philippe Gascard,2 Sri Kripa Balakrishnan,1 Jianxin Zhao,2 Sonia V. del Rincon,3 Charles Spruck,3 Thea D. Tlsty,2 and Beverly M. Emerson1,* 1Regulatory Biology Laboratory, Salk Institute for Biological Studies, 10010 North Torrey Pines Road, La Jolla, CA 92037, USA 2Department of Pathology, University of California, San Francisco, 513 Parnassus Avenue, San Francisco, CA 94143, USA 3Sanford Burnham Medical Research Institute, 10901 North Torrey Pines Road, La Jolla, CA 92037, USA *Correspondence: [email protected] http://dx.doi.org/10.1016/j.molcel.2013.04.029 SUMMARY been observed in human cancers (Saldan˜ a-Meyer and Recillas- Targa, 2011). Moreover, seminal studies have elegantly de- Cellular stress results in profound changes in RNA monstrated that de novo p53 translation mediated by the 60S and protein synthesis. How cells integrate this ribosomal protein RPL26 is required for efficient p53 accumula- intrinsic, p53-centered program with extracellular tion to direct specific cell-fate outcomes (Chen and Kastan, signals is largely unknown. We demonstrate that 2010; Schumacher et al., 2005; Takagi et al., 2005). b b TGF-b1 signaling interferes with the stress response Transforming growth factor (TGF- ) has a dual role in cancer through coordinate transcriptional and translational by acting as a tumor suppressor through cell-growth arrest and as a tumor facilitator at later stages (Massague´ , 2008). Central to repression of p53 levels, which reduces p53-acti- TGF-b1 signaling is phosphorylation of Smad 2/3 transcription vated transcription, and apoptosis in precancerous factors by the TGF-bRI/TGF-bRII receptor complex.
    [Show full text]
  • KLF6 Contributes to Myeloid Cell Plasticity in the Pathogenesis of Intestinal Inflammation
    ARTICLES KLF6 contributes to myeloid cell plasticity in the pathogenesis of intestinal inflammation WA Goodman1, S Omenetti1, D Date2, L Di Martino2, C De Salvo1, G-D Kim2, S Chowdhry2,3, G Bamias4, F Cominelli2,3, TT Pizarro1,2,5 and GH Mahabeleshwar1,2,5 Inflammatory bowel disease (IBD) is associated with dysregulated macrophage responses, such that quiescent macrophages acquire a pro-inflammatory activation state and contribute to chronic intestinal inflammation. The transcriptional events governing macrophage activation and gene expression in the context of chronic inflammation such as IBD remain incompletely understood. Here, we identify Kruppel-like transcription factor-6 (KLF6) as a critical regulator of pathogenic myeloid cell activation in human and experimental IBD. We found that KLF6 was significantly upregulated in myeloid cells and intestinal tissue from IBD patients and experimental models of IBD, particularly in actively inflamed regions of the colon. Using complementary gain- and loss-of-function studies, we observed that KLF6 promotes pro-inflammatory gene expression through enhancement of nuclear factor jB (NFjB) signaling, while simultaneously suppressing anti-inflammatory gene expression through repression of signal transducer and activator of transcription 3 (STAT3) signaling. To study the in vivo role of myeloid KLF6, we treated myeloid-specific KLF6-knockout mice (Mac-KLF6-KO) with dextran sulfate sodium (DSS) and found that Mac-KLF6-KO mice were protected against chemically-induced colitis; this highlights the central role of myeloid KLF6 in promoting intestinal inflammation. Collectively, our results point to a novel gene regulatory program underlying pathogenic, pro-inflammatory macrophage activation in the setting of chronic intestinal inflammation.
    [Show full text]